Is Egrifta (Tesamorelin) Legal in Michigan? How to Access It Legally
HealthRX.com
Egrifta is a prescription drug, with no compounding category
See the public record for Tesamorelin
At a glance
- FDA status / Prescription drug; BLA 022505 first approved November 10, 2010 [1]
- Current labels / Egrifta SV 2 mg vial and Egrifta WR 11.6 mg vial, both dated July 29, 2026 [4][5]
- Approved use / Excess abdominal fat in HIV-infected adults with lipodystrophy; not for weight loss [4][5]
- Daily dose / Egrifta SV 1.4 mg; Egrifta WR 1.28 mg; the labels say the two are not substitutable [4][5]
- Compounding / In no category of FDA's compounding lists and not on FDA's list of bulk substances that may raise significant safety risks when compounded [6][7][8]
- Sport / WADA S2.2.4: prohibited at all times [9]
What is the federal status of tesamorelin?
Egrifta (tesamorelin acetate) was first approved on November 10, 2010, as BLA 022505, a new molecular entity [1]. The current labels are Egrifta SV (2 mg vial) and Egrifta WR (11.6 mg vial), both dated July 29, 2026, and both once-daily subcutaneous injections [4][5].
Both labels indicate it only for reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. They say it is not indicated for weight loss management and that long-term cardiovascular safety has not been established [4][5]. Tesamorelin is a synthetic analog of human growth hormone-releasing factor, not growth hormone, and it stimulates the pituitary to release the body's own growth hormone [4].
Egrifta SV is 1.4 mg injected into the abdomen once daily, given immediately after reconstitution with the diluent provided (Sterile Water for Injection) [4]. Egrifta WR is 1.28 mg once daily, and its label says the two products are not substitutable [5]. The 2 mg daily dose used in the pivotal trials belonged to the original 1 mg/vial product [4].
What do the Michigan statutes say?
MCL 333.17745 sets requirements for prescribers who dispense prescription drugs directly, including licensing, recordkeeping and container labeling, subject to the exceptions stated in the law [2]. MCL 333.7201 gives the administrator of that article of the code authority to add, delete or reschedule substances in the statutory schedules [3]. Neither section is specific to tesamorelin.
Questions worth asking
What about compounded tesamorelin?
Tesamorelin is in no category of FDA's list for state-licensed pharmacies and physicians (updated May 14, 2026) and in no category of its list for outsourcing facilities (updated March 21, 2025) [7][8]. It is also not on FDA's list of bulk substances that may raise significant safety risks when compounded (content dated 04/22/2026) [6]. It is not among the six peptides named in HHS's draft enforcement-discretion policy for compounding, filed October 28, 2026 [10][11]. Compounded drugs are not FDA-approved; FDA does not review their safety, effectiveness or quality before they are marketed [11].
What do the labels warn about?
The labels contraindicate tesamorelin in disruption of the hypothalamic-pituitary axis, active malignancy, known hypersensitivity to tesamorelin or the product's excipients, and pregnancy [4][5]. Among patients treated 26 weeks, 47% had IGF-1 above 2 SDS and 36% above 3 SDS [4]. HbA1c of 6.5% or higher developed in 5% on tesamorelin versus 1% on placebo by week 26, hazard ratio about 3.3 (95% CI 1.4 to 9.6) [4].
What about antidoping rules?
WADA's Prohibited List names tesamorelin in S2.2.4 and prohibits it at all times, in and out of competition; it is on the 2026 List and remains on the 2027 List [9][12].
Frequently asked questions
Is Egrifta legal in Michigan?
Do I need a prescription for tesamorelin?
Is compounded tesamorelin FDA-approved?
Is tesamorelin allowed in sport?
References
Show all 12 referencesHide references
- Drugs@FDA: FDA-Approved Drugs.
- MCL - Section 333.17745 - Michigan Legislature.
- MCL - Section 333.7201 - Michigan Legislature.
- U.S. National Library of Medicine, DailyMed. Egrifta SV (tesamorelin) for injection, 2 mg vial prescribing information. Egrifta SV (tesamorelin) for injection, 2 mg vial label
- U.S. National Library of Medicine, DailyMed. Egrifta WR (tesamorelin) for injection, 11.6 mg vial prescribing information. Egrifta WR (tesamorelin) for injection, 11.6 mg vial label
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- World Anti-Doping Agency.
- Official web page.
- Official web page.
- World Anti-Doping Agency.